Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory follicular lymphoma after at least two lines of systemic treatment.
LAMPGEN ANALYSIS
Why it matters
This extends the CD19-directed CAR T-cell product to a later-line indolent lymphoma population.
What research teams should watch
Confirm the follicular lymphoma diagnosis and prior lines before starting a cellular-therapy referral.
PRIMARY RECORDS